As of the end of 2014, Par Pharma had more than 200 products in its pipeline, which included 115 Abbreviated New Drug Applications (ANDA) pending with the U.S. Food and Drug Administration (FDA). These represent $36.7 billion of combined annual sales for the corresponding branded products in 2014, including 32 potential first-to-file and six potential first-to-market opportunities.
In the filing, Par Pharma describes its segments:
Our company operates in two business segments, Par Pharmaceutical, which includes generic products marketed under Par Pharmaceutical and sterile products marketed under Par Sterile Products, LLC (“Par Sterile,” formerly known as JHP Pharmaceuticals, LLC), and Par Specialty Pharmaceuticals (“Par Specialty,” formerly known as Strativa Pharmaceuticals), which markets two branded products.
For 2014, Par Pharma had revenues of roughly $1.31 billion, with a compound annual revenue growth rate of 12.2%.
Par Pharma intends to use the net proceeds of this offering to repay indebtedness. It also intends to use the remainder of the net proceeds, if any, for working capital and other general corporate purpose including supporting strategic growth opportunities in the future.
IGXT was already involved with Par when they were a public company before TGP bought them, so I don't believe it will matter one way or the other. Par has been filing SEC documents right along, as they announced over a year ago that they would go public again...
News 
Market Data 
Discover 
